hy-0102
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT04914351)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
inhibitor - NKG2A
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06662669 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Shanghai YingLi Pharmaceutical Co. Ltd. |
| NCT06094777 | Phase 1 | Nov 10, 2023 | Fudan University, Shanghai YingLi Pharmaceutical Co. Ltd. |
| NCT04914351 | Phase 1 | Dec 1, 2021 | Government of China |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai YingLi Pharmaceutical Co. Ltd. | For profit | 2 | 2 | 2 | 2023 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Government of China | Government | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1